UCB (OTCMKTS:UCBJF) Stock Price Crosses Below 50 Day Moving Average – Should You Sell?

UCB SA (OTCMKTS:UCBJF) passed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $249.39 and traded as low as $240.24. UCB shares last traded at $240.24, with a volume of 10 shares trading hands.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on UCBJF shares. Jefferies Financial Group raised UCB to a “hold” rating in a research report on Monday, August 3rd. Piper Sandler reaffirmed a “neutral” rating on shares of UCB in a report on Wednesday, July 22nd. Five analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy”.

UCB Stock Performance

The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The business’s 50 day moving average price is $248.79 and its 200 day moving average price is $277.07.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on developing and commercializing medicines for severe diseases, particularly in immunology and neurology. The company’s research and development activities target conditions such as inflammatory disorders, epilepsy, and other diseases affecting the central nervous system.

UCB’s portfolio includes Bimzelx (bimekizumab) for certain inflammatory conditions, Cimzia (certolizumab pegol) for immune-mediated diseases, and Fintepla (fenfluramine), Briviact (brivaracetam), Keppra (levetiracetam), and Nayzilam (midazolam) for seizure-related disorders.